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Objective.—To assess the effect of acetazolamide (Az) on exercise performance during early
acclimatization to altitude.
Methods.—Az (250 mg twice daily) or placebo was administered for 3 days in a double-blind,
randomized manner followed by a rapid ascent to 3459 m in the Italian Alps. Twenty healthy adults
(age range, 18–67 years) were tested at 60% of sea-level peak power output for 15 minutes on a bicycle
ergometer after 16 to 27 hours of altitude exposure. Exercise performance was measured in relation to
peripheral oxygen saturations measured from pulse oximetry (SpO2), Lake Louise acute mountain
sickness (AMS) score, and perceived difﬁculty.
Results.—At altitude, resting SpO2 was higher in the Az group compared with placebo (P o .001).
The highest AMS scores were in 4 of the placebo individuals with the lowest resting SpO2 (P o .05).
During the exercise test, SpO2 fell in all but 1 subject (Po .001) and was reduced more in the Az group
(Po .01). Four Az and 1 placebo subject were unable to complete the exercise test; 4 of these 5 had the
largest fall in SpO2. The perception of exercise difﬁculty was higher in the Az subjects compared with
those taking the placebo (P o .01). There was an age relationship with exercise limitation; 4 of the 9
older than 50 years failed to complete the test whereas only 1 of 11 younger than 50 years failed, and
there were no failures in the 6 younger than 30 years (P o .05).
Conclusions.—In this study group, and despite higher resting SpO2, Az may have compromised
exercise at 3459 m altitude during early acclimatization, particularly in older subjects.
Key words: acetazolamide, exercise, altitude
Introduction
The use of acetazolamide (Az) for the prevention of acute
mountain sickness (AMS) has been debated for 50 years,
but 2 recent meta-analyses have strongly supported its
effectiveness. In 2012, Kayser and colleagues reviewed 24
placebo-controlled trials comparing 1011 Az-treated indi-
viduals with 854 placebo-treated individuals and showed
convincing evidence of its value.1 Escalating doses from
250 mg, to 500 mg and 750 mg per day revealed increasing
reduction in AMS symptoms by 45%, 50% and 55%
respectively, compared with placebo. Another systematic
review and meta-analysis again scrutinized the published
studies and conﬁrmed the overall positive beneﬁts of Az.2
This study was supported by a linked editorial suggesting a
more personalized approach was indicated.3
In spite of this overwhelming evidence, many are
unwilling to take medication that may have unpleasant
side effects. Paresthesias and the altered taste of carbo-
nated drinks can be most irritating, although they are
less apparent with lower doses. In addition, there are
concerns that exercise capacity might be reduced at
altitude because this has been observed when taking Az
at sea level.4,5 Moreover, exercise tests using hypoxic
gas mixtures to simulate altitude in the laboratory have
not been consistent. Some have demonstrated impaired
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exercise performance,6,7 whereas others showed the
opposite, that Az improved arterial oxygenation during
exercise.4,8 However, the total numbers of individuals
investigated have been small, typically 6 per study. In
addition, the participants have been young, whereas
trekkers to altitude often tend to be older. For example,
in one Japanese report 70% of the subjects were older
than 50 years.9 When Az is commenced at high altitude
in acclimatized individuals, there is again uncertainty
about its effect on exercise. One early study showed 2 of
4 people had reduced exercise capacity at 6300 m,10
whereas a study of 15 subjects showed no adverse
effects at 4700 m after 10 days of acclimatization.11
Unfortunately, none of these studies addressed the use of
Az in practice. Normally, Az is taken prophylactically
for 1 to 2 days before altitude exposure.1 Typically,
individuals then ascend to between 3500 m and 5500 m
over the following week or so. Such altitude exposure
is much longer than that undertaken in laboratory
experiments, and there is usually some degree of AMS.
Only 1 study has evaluated this treatment schedule.12
Twenty individuals prophylactically took 500 mg of Az
or placebo daily on an ascent to 4,846 m. At 10 days, the
Az group performed better with 20% less reduction in
exercise performance than the placebo group, and this
was associated with retention of muscle mass. Clearly,
Az was having a quite different effect from its use in
short-term treatment studies.
These differing data and limited long-term studies do
not provide a consensus regarding the altitude or the
stage in acclimatization when Az is beneﬁcial, neutral, or
possibly detrimental to exercise. The purpose of this
investigation was to assess whether Az affected exercise
performance at modest altitude in the early phase of
altitude acclimatization. A height of 3459 m was chosen
as this was sufﬁcient to induce a modest degree of AMS,
and the availability of a comfortable, easily accessible
refuge allowed well-controlled exercise testing.
Methods
SUBJECTS AND DRUG TRIAL OF AZ VS
PLACEBO
Twenty healthy individuals were recruited. Ages ranged
from 18 to 67 years (mean age, 43 ! 16.5 years). There
were 6 women, 4 between 20 to 23 years and 2 older
than 50 years. Menstrual cycle phase was not recorded.
Sixteen individuals had previous experience of altitude
and were classiﬁed into low, medium, or high AMS
susceptibility, but none had suffered from pulmonary or
cerebral edema. In 4 individuals, AMS susceptibility was
unknown. No participant had resided above 1500 m in
the previous 2 months. Apart from 1 subject with mild
hypertension who was taking the angiotensin-converting
enzyme inhibitor, ramipril (5 mg/d), none was taking any
relevant medication and all had refrained from intense
physical activity on the days before testing. All were
kept naive regarding the medication and expected out-
comes of the study. Because of obvious side effects from
Az administration such as paresthesias, individuals were
requested not to discuss any aspects of their medication
with others, including the investigators.
Individuals were paired for similar characteristics by
hierarchy of importance for 1) previous AMS suscepti-
bility, 2) male/female, and 3) age. There were no
signiﬁcant differences between the groups for these 3
variables, nor weight or resting pulse rate. Each pair
received 250-mg capsules of Az or placebo (starch)
randomly allocated by independent observers, with
blinding to subjects and investigators alike. Capsules
were taken twice daily starting 3 days before the altitude
exposure for a total of 9 doses.
EXERCISE TEST
This was performed on a specially constructed, light-
weight (25 kg), horizontal bicycle designed for altitude
studies (Alti Cycle).13 In use, the individual lay supine,
constrained by a shoulder harness, with feet strapped into
the pedals. Multistage gearing provided high inertia from
a 2-kg ﬂywheel rotating at 2900 rpm at 60 rpm pedaling
speed, thereby mimicking the sensation of cycling on a
normal bicycle. A remotely controlled brake acted on the
ﬂywheel to provide controllable resistance, and power
output and cadence were measured via a strain-gauged
crank-set (Schoberer Rad MeBtechnik, Julich, Germany)
linked to a laptop computer. This mode of exercise was
chosen because it allowed other studies.
A submaximal exercise test was selected to induce
considerable pulse oxygen saturation (SpO2) desaturation
at altitude and with the expectation that it would be
completed by all individuals. To establish the exercise
intensity required before ascent, 1 individual was exer-
cised on different days for 15 minutes at 80%, 70%, and
60% of their peak power output (PPO) in a normobaric
hypoxic chamber (TISS Model 201003-1; TIS Services,
Mestead, UK) at an oxygen depletion similar to 3,459 m
(fractional inspired oxygen [FIO2], 0.13). Only the 60%
PPO was sustainable for 15 minutes, and this was used at
altitude for all subjects.
The exercise test at sea level was undertaken on days
6 and 7 before ascent by each individual in the following
manner. After a warm-up for 2 to 3 minutes at 50 to 80
W and 60 rpm, the brake resistance was increased by
10- to 20-W intervals every 60 seconds until power could
not be sustained. The last minute of constant power was
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selected as the PPO. Peak pulse rate was recorded and
compared with the theoretical peak pulse rate of 220
minus age to provide some assurance that individuals were
exercising at or near their maximum. On completion of
each test at altitude, the individual was asked to indicate
whether the perceived exertion was easy, medium-hard, or
hard, to which was added an involuntary category of fail.
ASCENT PROFILE AND ALTITUDE STUDIES
Individuals travelled from sea level to Cervinia in Italy
(2050 m) or Zermatt in Switzerland (1608 m) during a
12-hour period. Final ascent to Refugio Testa Grigia
(3459 m), in Italy, was by cable car over a 1-hour period
to arrive at 4:00 PM.
Altitude exercise tests were commenced at 8:00 AM the
following day and completed by 7:00 PM. Paired
individuals were tested within an hour of each other so
that altitude exposure times were similar. Pairs tested
early had approximately 16 hours of altitude exposure,
whereas later pairs had up to 27 hours of altitude
exposure. Each person was asked immediately before
the exercise test by the investigators as to their view of
which medication they thought they were taking, but the
allocation code was unknown.
Self-assessed questionnaires of the Lake Louise Scor-
ing System for AMS14 were recorded on the evening of
arrival, the following morning, and immediately before
and after the exercise tests. Because subjects were tested
at different times of the day, a mean AMS score was
obtained as a measure of accumulated AMS symptoms in
relation to hypoxia exposure. This was the mean value of
the morning Lake Louise score and that immediately
before the exercise test. SpO2 and pulse rate were
measured using an Ohmeda Biox 3740 Pulse Oximeter
(Datex-Ohmeda Ltd, Hatﬁeld, UK). Three recordings
were made before the exercise test, and the mean was
calculated. Measurements were also recorded every 5
minutes during the test. The calculated reduction in SpO2
was from the mean preexercise level to the lowest level
recorded during exercise.
STATISTICAL ANALYSES
Statistical analyses were performed using SPSS version
21 (IBM Corp, Portsmouth, UK). Box and whisker plots
for medians and ranges, Mann-Whitney test for differ-
ences of means, and Spearman’s correlation for compar-
ison of groups were used.
ETHICS
The study was approved by Chichester University
Research Ethics Committee (protocol number: 121339)
and was performed according to the Declaration of
Helsinki. All individuals gave signed informed consent.
Results
The 2 treatment groups were well matched for suscept-
ibility to AMS, male/female ratio, and age (Az, 41 years;
placebo, 44 years; 450 years: Az, 4; placebo, 5).
Median PPO achieved at sea level was not signiﬁcantly
higher in the placebo group (mean !1 SD: Az, 210 ! 29
vs placebo, 250 ! 47). The trial capsules were taken by
all individuals successfully. A questionnaire recorded
immediately before the exercise test (but analyzed later)
indicated that 15 had correctly guessed their medication.
At altitude (Figure 1), resting SpO2 before the exercise
tests were higher in the Az group compared with placebo
(Mann-Whitney test, mean !1 SEM: Az, 91.7 ! 0.08;
Pl, 85.4 ! 0.83; P o .001), and the 4 individuals with
the lowest resting SpO2 had the highest AMS scores
(Spearman’s correlation; P o .05). Comparison of SpO2
for subjects paired for AMS susceptibility showed that
all those taking Az had higher values than their placebo
partners (P o .001). There were insigniﬁcant trends to a
lower SpO2 with increasing age, plus lower AMS scores
and rising SpO2 as the day progressed. Seven of 10
matched pairs had higher AMS scores in the placebo
individual compared with their Az partner and 1 was
the same.
The exercise test was technically satisfactory in all
subjects. SpO2 fell in all but 1 subject during the test
(mean ! SEM: Az group, 91.7% ! 0.8% to 81.7% !
2.4%; placebo group, 85.4% ! 0.83% to 79.2% ! 1.1%;
P o .001) and the fall was greater in the Az group
(P o .01). In the 6 youngest subjects, the 3 taking Az
Figure 1. Peripheral O2 saturations (SpO2) in placebo and acetazo-
lamide groups at 3459 m before and during exercise. Acetazolamide
individuals had higher concentrations before exercise (P o .001) and
had a greater fall during exercise (P o .005) than placebo individuals.
Box and whisker plots show medians and ranges for the 2 groups.
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had the highest SpO2 at altitude (Figure 1) and higher
than their corresponding control partners, both at rest
(Az, 94%, 94%, 92% vs placebo, 90%, 88%, 85%) and
during the exercise test (Az, 89%, 89%, 88% vs placebo,
80%, 80%, 79%), and SpO2 fell less during the exercise
test (Az fall: 8%, 6%, 4% vs placebo fall, 10%, 9%, 8%).
There were insufﬁcient subjects for statistical analysis.
Five subjects failed to complete the exercise test, with 4
of the 5 having the largest fall in percentage SpO2
(Figure 1). Furthermore, the placebo subject who failed
had the highest AMS score of 8 on awakening and 4 before
the exercise test. Four of the subjects complained of
dyspnea as the limiting factor, and in the ﬁfth subject it
was leg fatigue. No objective measurements of ventilation
were made. There was an age relationship with exercise
failure: 4 of the 9 subjects older than 50 years failed the
test, whereas only 1 of 11 younger than 50 years failed and
there were no failures in those younger than 30 years (Po
.05). The perception of difﬁculty was higher in the Az
subjects compared with the placebo subjects (Figure 2;
Spearman’s correlation, P o .01) in spite of a higher
starting SpO2. There were insufﬁcient subject numbers to
show a relationship between AMS susceptibility and
exercise failure. The 1 individual taking ramipril (and
Az) successfully completed the test.
Discussion
The results show that exercise performance at 3459 m
was reduced in many subjects taking Az. The reduction
was in terms of its perceived difﬁculty and the failure to
complete the test in 4 subjects of whom 3 had large
reduction in SpO2. This was not related to AMS suscep-
tibility. It was also not related to exercise performance
requirements because each subject had to perform at
60% of their sea level PPO. As expected, the Az group
had higher resting SpO2 at altitude before the test and
they had fewer AMS symptoms. In contrast, placebo
subjects had lower SpO2 at rest, but these were better
maintained during the exercise tests compared with the
Az subjects. The 1 placebo exercise test failure had the
highest Lake Louise AMS score of 8 on awakening and
the highest of 4 before the exercise. We speculate that
his exercise performance was compromised by accumu-
lated edema ﬂuid that may have reduced pulmonary gas
exchange.
There have been several detailed publications of the
effect of Az on exercise at reduced oxygen concentrations
during early exposure to hypoxia. All were for subjects
exposed to hypoxic gas mixtures commencing immediately
before the exercise tests. Schoene and colleagues inves-
tigated 6 men (age, 23–35 years) in a crossover study of 3
250-mg doses of Az over 24 hours and using an FIO2 of
0.118 (!4800 m), compared with an FIO2 of 0.21 at sea
level.4 On Az, arterial oxygenation was higher during
exercise with an increase in exercise endurance at
maximal oxygen consumption (VO2max). Jonk and
colleagues investigated 6 trained men (age, 26.3 ! 4.6
year) in a crossover study at an FIO2 of 0.125 (!4400 m)
and used 3 250-mg doses of Az over 24 hours; they noted
improved arterial oxygenation during exercise but there
were no exercise endurance data.8 Three studies have
shown a reduction in exercise performance on Az during
hypoxia. McLellan and colleagues performed a crossover
study in 4 subjects using 500 mg Az daily for 2 days at a
simulated altitude of 4200 m, and noted a slightly reduced
time to exhaustion at 90% VO2max on Az.
6 Stager and
colleagues investigated 27 subjects (age, 28.7 ! 2.9 years)
in a crossover study using 2 250-mg doses of Az over 24
hours at a simulated altitude of 4270 m and showed a 26%
reduction in time to exhaustion on a submaximal exercise
test.5 Garske and colleagues investigated 9 subjects (age,
27.9 ! 2.9 years) in a crossover study and used 500 mg of
Az twice daily for 5 doses at an FIO2 of 0.13 (!4200 m);
they showed improved arterial oxygenation at maximal
exercise, but maximal power was reduced and leg fatigue
was greater.7 Interestingly, the ﬁrst 2 studies at 4800 m and
4400 m showed beneﬁt from Az, whereas the latter 3 at
slightly lower altitudes (!4200 m) showed reduced
exercise performance.
Our study differed from these reports in 3 main aspects.
First, subjects were exposed to altitude for 18 to 27 hours
before the exercise test and, importantly, during a period of
sleep with its attendant hypoxia. This caused a measureable
amount of AMS symptoms, which were slightly less in the
Az group (although not signiﬁcant). Second, the altitude of
our study at 3459 m (FIO2 !0.13) was considerably lower
than the reported laboratory experiments but still showed
Figure 2. Perceived exercise difﬁculty for placebo individuals at 3459
m compared with their matched acetazolamide partners (P o .01).
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impaired exercise performance on Az. By comparison, a
study at 4846 m and after 10 days of altitude exposure had
shown superior exercise performance on Az.12 These
contrasting results suggest that there may be a critical
combination of altitude gain or hypoxia duration above
which Az improves exercise performance by reducing the
incidence of AMS. The third difference in our study was
the wide age proﬁle. The 3 subjects taking Az who were
younger than 30 years performed well with no exercise test
failures. Furthermore, SpO2 was considerably higher during
exercise than in aged-matched placebo controls. If we had
investigated only these 6 young subjects (as for most
laboratory studies), we would have concluded that Az had
no adverse effect on exercise and had a beneﬁcial effect on
SpO2. Why older individuals were compromised by exer-
cise is unclear. Maybe they had age-related cardiovascular
impairment, altered alveolar ventilation, or renal impair-
ment, but there was no evidence of disease and all were ﬁt
individuals. One might also speculate that older people
metabolize Az differently. There are more than a dozen
different carbonic anhydrase isoenzymes, and some may be
inhibited differently with age or in dissimilar individuals.
Whatever the mechanism, more studies on older subjects
and at higher altitudes are warranted.
It is important to remember that maximal or submax-
imal exercise cannot be maintained for long periods, so
bears little resemblance to the prolonged periods of
lower-intensity exercise that occurs on treks. Brief
periods of excessive oxygen desaturation that might
occur with Az during exercise are insigniﬁcant compared
with oxygen saturations that are 15% to 20% higher
throughout the day and night.15 Over many days this
could have an important accumulative effect resulting in
better sleep, less appetite suppression, and greater
retention of muscle mass, any of which could lead to
better exercise performance.
LIMITATIONS OF THIS STUDY
The investigation contained only 20 individuals so was
relatively small but nevertheless larger than most laboratory
series. In addition, the altitude attained was modest, and
there was no crossover trial. The latter is difﬁcult to achieve
as a mountain study. A week or more is required to
deacclimatize and to wash out Az, so all individuals would
need to return to sea level, the United Kingdom in our case.
As regards the exercise test, a VO2max or endurance test
might have provided more information. However, such
studies are more complicated, and we wanted to complete
the study in a single day so that altitude exposure would not
be too disparate between individuals. We chose 500 mg per
day of Az to be comparable with existing chamber experi-
ments. A commonly recommended dose for trekking is 250
mg per day, which might have less effect on exercise
performance and merits further study.1 Exercise perfor-
mance using a horizontal bicycle ergometer is slightly less
than that on a vertical bicycle, but all subjects were studied
in the same manner. Other limitations are the lack of
continuous recordings of SpO2, pulse rate, blood pressure,
etc, and we had no measure of pulmonary gas exchange.
Conclusions
We have shown that during early acclimatization to 3459
m, 500 mg of Az daily reduces the ability to exercise
hard. Placebo subjects experienced more AMS than
those on Az but were able to exercise to a greater
degree, had lower SpO2, and experienced less fatigue. In
this small study group, exercise limitation was more
frequent in the older members, an age effect that has not
been observed previously. These results add to the
uncertainty of the effect of Az on exercise at altitude.
Although it is entirely appropriate that Az should be
widely used for preventing AMS, more studies on
exercise performance are required, particularly using
different medication doses, different ascent proﬁles,
and on elderly people.
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